Google
KALA — KALA PHARMACEUTICALS INC (Healthcare >> Biotechnology)
KALA FAQ
What is KALA's P/E ratio?
KALA PHARMACEUTICALS INC (KALA) currently trades at a P/E ratio of 55.82.
What is KALA's ROE?
KALA PHARMACEUTICALS INC reports a Return on Equity (ROE) of -182.64%.
What is KALA's dividend yield?
KALA PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is KALA's Deepscope Quality Score?
Deepscope rates KALA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KALA?
Deepscope's AI Timing Score for KALA is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KALA belong to?
KALA PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.06
Price
-0.17
(-7.62%)
Day Change
|
|
|---|
KALA, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.06 |
| PBV / Sector |
3.56 / 4.63
|
| Earning Per Share | -1.06 |
| PE / Sector |
55.82 / 17.43
|
| PEG or PE/Growth / Sector |
-1.09 / 0.53
|
| Average 1M Daily Value |
0.25 M
GREAT
|
| Average 1W Daily Value |
0.23 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:47 |
| Symbol | KALA |
| Name | KALA PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 18.59 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 38.30 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1167 Massachusetts Avenue, Arlington, MA, United States, 02476
Phone: 781 996 5252
Website: https://www.kalarx.com
Sector: Healthcare >> Biotechnology
Description: KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
